Epion Therapeutics
Epion pioneers minimally invasive, transformative treatments for corneal disease, enabling early intervention globally.
Founded
2012Epion pioneers minimally invasive, transformative treatments for corneal disease, enabling early intervention globally.
Epion Therapeutics, founded by experts in ophthalmology, focuses on developing minimally invasive treatments for corneal diseases, particularly keratoconus. Their core mission is to provide early intervention solutions that improve patient outcomes globally. The company's flagship product, EpiSmart, is a cross-linking system designed to treat keratoconus without disrupting the epithelium, allowing patients to quickly return to their normal activities. Epion aims to revolutionize corneal disease treatment with innovative and patient-friendly solutions.
Notable figures affiliated with Epion include Michael W. Belin, MD, the Chief Medical Officer, who is renowned for developing the Belin ABCD Progression Display. The company has garnered support from leading experts in the field and has made significant strides in corneal disease treatment. Epion's impact lies in its potential to transform the standard of care for keratoconus patients, offering a less invasive and more efficient treatment option that can be adopted globally.
Companies similar to Epion Therapeutics include Glaukos, Teclens, EpiEP and Eyedea Medical.
Epion Therapeutics was founded in 2012.
Epion Therapeutics' headquarters is located in Burlington, MA, US.
Epion Therapeutics' most recent funding round was for $32M (USD) in September 2022.
As of Sep 30, 2022, Epion Therapeutics has disclosed funding of $32M (USD). Undisclosed round amounts are excluded.
Epion Therapeutics has 6 employees as of Feb 4, 2024.
Eyedea Medical
eyedeamedical.com
